interpreted and adopted in a manner supportive of public health and easy access to medicines for the citizens of all WTO member countries.
Introduction phenomenon using the two-level game theory (Putnam, 1988, p. 433-452) . The theory helps us understand how domestic and international pressures synchronously caused India's shifting position towards broader IPR protection. It elaborates that there are Level I and Level II in the process of 'ratifying' an international agreement. Level I is about bargaining between negotiators in the international arena where there were Indian and foreign governments, Non-Governmental Organizations (NGOs) with their valuable insights that promoted the interest of the public domain, and business sectors that heavily allocated funding for groups like think-tanks to advise the negotiating issues at the WTO. At Level II, there were separating domestic discussions between constituents within the represented area of each of the international negotiators. This part of the theory helps to select government, NGOs, and business groups as the domestic 'constituents' that were continuously involved in the IPRrelated policymaking process in India. The significance of both levels led the negotiators not only to focus on bargaining at the international level but also to take into full consideration the interests of domestic constituents, which had been negotiated at Level II.
This article is written as follows: the following part will discuss India's aversion to IPRs protection, which mostly occurred before Within the Indian bureaucracy, the challenges to IPR protection were apparent. In the parliament, the debate on whether or not to support IPR protection gained prominence during the process of the Patents Act 1970 amendment. The first bill proposed to amend India's existing regulation to comply with TRIPS was the 1994 Patents Ordinance. This failed because it was proposed by the President but was not approved by the parliament within six weeks. In India, the president may adopt an ordinance in the period of emergency, yet it has to be approved by the parliament in six weeks to be an act (Hardgrave & Kochanek, 2008, p. 84 ). This explained why the first bill failed.
To prove its commitment to the TRIPS council, the government further introduced Patents (Ganguli, 1999, p. 279 ).
In 1998, another patent bill was introduced but failed to become an act due to strong resistance in Lok Sabha. Janata Dal, an Indian minority party that was in the forerun during the negotiation, argued that the bill provided low safeguards and insufficient implementation of TRIPS flexibilities (Winanti, 2011, p. 169 1994 -1995 (Ramanna, 2003 .
Furthermore, NWGPL constructed
People's Commissions, which operated one after another, following the most recent issues list due to its leadership in opposing IPR protection (Chaudhuri, 1993 (Chaudhuri, , p. 1864 . More pressures were enforced in April 1992 when the US President put off the duty-free benefits to imports of chemical and pharmaceutical products from India, which was costing Indian exports as much as $60 million-owing to the fact that India had failed to protect the American IPRs (Chaudhuri, 1993 (Chaudhuri, , p. 1864 The NGOs adopted many strategies to pursue their goals of opposing IPR protection.
Firstly, they conducted workshops and (Ludwig, 2015) .
The big pharmaceutical companies did not only push their governments to safeguard IPR protection through international organisation, but also lobbied the governments to put bilateral pressures on countries that breached IPR protection. As a US media reported, the pharmaceutical companies had aggressively lobbied the government to pressurise India toward strong patent legislations, noting that India had been the country with loose IPR protection (Ludwig, 2015) . In South Africa, Pharmaceutical Association (IPA), with a more positive view on patent regime (Sinha, 2016, p. 143-144) . This roughly marked the turning point for Indian pharmaceutical businesses as they were moving toward accepting patent protection on drugs.
In regard to stronger IPR protection to also include GRTKF, data showed that to date, there were no challenges from the business sector. If sometime in the future it is found out that the Indian business groups find their interests competing to that of the indigenous people, then they would need to turn into investing on R&D, in the current era that accommodates strong IPRs protection.
By massively investing on R&D, their focus of doing business should be on discovering new drugs instead of copying existing drugs or even making use of the existing knowledge owned by their nation's indigenous people.
International Level
Similar to the previous period where India was supported by developing countries With strong support from developing countries and remarkable moves followed by developed countries toward GRTKF protection, India sensed only limited challenges from the big pharmaceutical industry. True that these businesses still allocated a huge portion of their profits to lobby the government to oppose GRTKF protection. However, the decisions of the US and the UK to sign the TKDL Access Agreement prove that India shall not imply these businesses' moves as a significant challenge, simply because they were not.
The This article wishing to fulfill its main task, has proven that India has the capability, though as a developing country, to maintain its sovereignty in the face of massive pressures from foreign countries and international institutions. In preparation to face the GRTKF protection era, future research is needed on 
